HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lead Acetate Ban A Go As US FDA Denies Combe’s Request For Hearing

Executive Summary

Lead acetate’s use as a color additive in cosmetic products will no longer be authorized in the US beginning on 6 January 2022, and the agency will exercise enforcement discretion for a year afterward. A 2018 hearing request from hair dye marketer Combe Inc. was denied by the agency on 7 October.   

You may also be interested in...



US FDA Cosmetics Director Lists Talc, Formaldehyde In Hair Smoothers Among Priorities

Linda Katz, director of the FDA’s Office of Cosmetics and Colors, touched on cosmetics modernization legislation in her 21 September presentation on agency priorities at the Independent Beauty Association’s virtual FDA Cosmetics Regulations Workshop.

US FDA Wants Remote Regulatory Assessment Authority For Cosmetics – FY 2023 Budget Justification

After freezing its routine inspection activities at the height of the COVID-19 pandemic, the FDA adapted its oversight approach visibly in the drug and medical devices sectors, including with voluntary remote regulatory assessments. The agency now seeks authority to continue that work on a non-voluntary basis across all FDA-regulated programs.

FDA May Put Hold On Lead Acetate Hair-Dye Rule; Manufacturer Combe Demands Hearing

Grecian Formula marketer Combe likens the process and calculations that informed FDA’s final rule against lead acetate to “a child’s game of telephone.” Environmental Defense Fund warns that if FDA grants Combe’s request – which the NGO suspects is unavoidable – it intends to cross-examine the company’s witnesses about consumer complaints and their handling in the firm’s past.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS151841

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel